Asper Biotech on CE
Updated Noonan Syndrome Panel
Eneli Oitmaa, the CEO of Asper Biotech gives an interview to the CE about the current situation in genetic testing services in Asper Biotech and also company’s future perspectives in biotechnology market. We have added six new genes (CBL, HRAS, KAT6B, MAP2K2, SHOC2, SPRED1) to the Noonan syndrome NGS panel.
Learn more >> Learn more >>

CLIA certificate #99D2046227
ISO 15189:2008 certificate #L259
ISO 9001:2008 certificate #EST04512A

Cystic Fibrosis External Quality Assessment Certificate
Hereditary Deafness External Quality Assessment Certificate


Asper Ophthalmics
Asper Oncogenetics
Asper Reprogenetics
Asper Biotech Varia
Asper Animal Genetics